ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Regulation FD Disclosure
Item7.01 Other Events.
On December5, 2016, Adaptimmune Therapeutics plc (the Company)
issued a press release announcing that it has initiated a study
of its NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma
(MRCLS). Patient screening is underway, and the results from this
study in up to 15 patients will inform a potential future
registration trial. The initiation of screening in this study
meets a milestone set forth in the Companys strategic
collaboration agreement with GlaxoSmithKline plc (LSE/NYSE: GSK).
The press release is furnished as Exhibit99.1 to this Current
Report on Form8-K and is incorporated by reference herein.
The information in Item7.01 of this Form8-K (including
Exhibit99.1) shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference under the Securities Act of
1933, as amended, except as expressly set forth by specific
reference in such a filing, regardless of any general
incorporation language in any such filing, unless the Company
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits. The following exhibit is furnished as part of this
Report on Form8-K:
|
ExhibitNo. |
|
DescriptionofExhibit |
|
99.1 |
Press Release dated December5, 2016. |
About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region. ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Recent Trading Information
ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) closed its last trading session down -0.11 at 4.05 with 109,191 shares trading hands.